Menu
Back to User profile » Dr Leopoldo Martín Baiza-Durán
Papers published by Dr Leopoldo Martín Baiza-Durán:
Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks
Contreras-Salinas H, Orozco-Ceja V, Romero-López MS, Barajas-Virgen MY, Baiza-Durán LM, Rodríguez-Herrera LY
Clinical Ophthalmology 2022, 16:3753-3762
Published Date: 15 November 2022
Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery
Palacio-Pastrana C, Muñoz-Villegas P, Dániel-Dorantes F, Sánchez-Ríos A, Olvera-Montaño O, Martínez-Montoya YI, Quintana-Hau JD, Baiza-Durán LM
Medical Devices: Evidence and Research 2022, 15:293-305
Published Date: 24 August 2022
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination [Erratum]
Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Vázquez-Álvarez AO, Bautista-Castro MA, Rodríguez-Herrera LY
Clinical Ophthalmology 2022, 16:245-246
Published Date: 4 February 2022
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
Muñoz-Villegas P, Navarro-Sánchez AA, Sánchez-Ríos A, Olvera-Montaño O, Baiza-Durán LM
Therapeutics and Clinical Risk Management 2021, 17:1123-1134
Published Date: 21 October 2021
Real-Life Active Surveillance of a Naphazoline/ Hypromellose Fixed Combination’s Safety Profile in Peruvian Population
Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Orozco-Ceja V, Rodríguez-Herrera LY
Integrated Pharmacy Research and Practice 2021, 10:127-133
Published Date: 16 October 2021
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L
Journal of Experimental Pharmacology 2021, 13:545-554
Published Date: 31 May 2021
Ophthalmic Solution Safety Profile: Active Surveillance of a Sodium Hyaluronate/Chondroitin Sulfate Combination in Peruvian Population
Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Orozco-Ceja V, Rodríguez-Herrera LY
Drug, Healthcare and Patient Safety 2021, 13:117-123
Published Date: 27 May 2021
Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Vázquez-Álvarez AO, Bautista-Castro MA, Rodríguez-Herrera LY
Clinical Ophthalmology 2021, 15:583-590
Published Date: 16 February 2021
Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, Suárez-Velasco R, Montes-Salcedo M, Fernández de Ortega L, Nasser-Nasser L, Baiza-Durán L, Olvera-Montaño O, Muñoz-Villegas P
Clinical Ophthalmology 2020, 14:1581-1589
Published Date: 12 June 2020
Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model
Olvera-Montaño O, Baiza-Duran L, Quintana-Hau JD, Quiñonez-Alvarado MG, Zeng W, Gong L, Muñoz-Villegas P
Drug Design, Development and Therapy 2019, 13:3813-3821
Published Date: 4 November 2019
Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
Chávez-Mondragón E, Palacio C, Soto-Gómez A, Villanueva-Nájera M, De Wit-Carter G, Suárez-Velasco R, Baiza-Duran L, Olvera-Montaño O, Muñoz-Villegas P
Clinical Ophthalmology 2019, 13:781-787
Published Date: 2 May 2019